Compound having therapeutic activity against mycobacterium avium complex infection, and method for producing same
The purpose of the present invention is to provide a novel compound which has antibacterial activity against Mycobacterium avium and Mycobacterium intracellulare that are causative bacteria of MAC infection and which is different in backbone structure from known drugs for treatment of MAC infection. One aspect of the present invention relates to a compound of Formula (I) [where R 1 has the same meaning as described in the specification and claims] or a salt thereof, or a solvate thereof. Another aspect of the present invention relates to a method for producing the compound of Formula (I) or a salt thereof, or a solvate thereof, and a therapeutic agent for Mycobacterium avium complex infection (MAC infection), which comprises the compound or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof as an active ingredient.
1. A compound of Formula (I):
wherein,
R 1 is 2-methylpropan-1-en-yl, 4-(2-methylpropionylamino)-phenyl, 3-methylpentan-1-en-yl, 4-(4-hydroxymethyl-2,2,4-trimethyl-5-oxoimidazolidin-1-yl)- phenyl, 1-methylpropan-1-en-yl, 1-methylpropyl, or 3 -methylbutan-l-en-yl
or a salt thereof, or a solvate thereof.
2. The compound according to claim 1 , wherein R 1 is 2-methylpropan-1-en-yl.
3. A method for producing the compound or a salt thereof, or a solvate thereof according to claim 1 , which comprises:
a compound accumulation step of culturing in a medium a microorganism which is Streptomyces OPMA40551 strain (Accession No. NITE BP-02510) to accumulate the compound of Formula (I) in the medium; and
a compound purification step of purifying, from a culture broth of the microorganism, the compound of Formula (I) obtained in the compound accumulation step.
4. A pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof according to claim 1 , and one or more pharmaceutically acceptable carriers.
5. The pharmaceutical composition according to claim 4 for use in preventing or treating Mycobacterium avium complex infection (MAC infection).
6. A method for preventing or treating a symptom, disease and/or disorder which is an infection with one or more bacteria, which comprises administering an effective amount of the compound or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof according to according to claim 1 to a subject in need of prevention or treatment of the symptom, disease and/or disorder.
7. The method according to claim 6 , wherein the symptom, disease and/or disorder which is an infection with one or more bacteria is one or more symptoms, diseases and/or disorders selected from the group consisting of Mycobacterium avium complex infection (MAC infection) and tuberculosis.